Slide 1: Orion Interim Report 1-9/2017
Orion Interim Report 1-9/2017
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Centenary year has continued as planned
Centenary year has continued as planned ● Net sales were at previous year’s level. 1-9/2016 1-9/2017 ● Easyhaler product family maintained good growth 794 804 and geographical expansion. Sales of budesonide- formoterol Easyhaler formulation have now commenced also in Germany and the United Kingdom,
Slide 4: Geographical breakdown of net sales
Geographical breakdown of net sales 1-9/2017 Orion’s sales network Finland 15% Scandinavia 30% 7% Other Europe North America 18% 30% ROW 4 26 October 2017 Interim Report 1-9/2017 © Orion Corporation
Slide 5: Breakdown of net sales by business division
Breakdown of net sales by business division Net sales, 1-9/ 1-9/ EUR million 2017 2016 Change Proprietary Products Specialty Products 387 372 +4% 3% 5% 5% 32% Specialty Products Proprietary Products 261 269 -3% 7% Animal Health Animal Health 56 54 +4% Fermion Fermion 41 33 +23% Contract Contract man
Slide 6: Pharmaceuticals business
Pharmaceuticals business 6 26 October 2017 Interim Report 1-9/2017 © Orion Corporation
Slide 7: Best-selling pharmaceuticals 1-9/2017
Best-selling pharmaceuticals 1-9/2017 Net sales, Change vs. Product Indication EUR million 1-9/2016 1. Parkinson’s disease 80 -22% 2. Asthma, COPD 55 +18% 3. Intensive care sedative 47 +16% Rheumatoid arthritis, inflammatory 4. bowel diseases 45 +44% 5. Acute decompensated heart failure 43 +5% 6. An
Slide 8: Proprietary Products
Proprietary Products Breakdown of net sales ● As expected, sales of Stalevo, Comtess and Comtan continued to decline, but growth in Stalevo, Comtess Easyhaler product family, Dexdor and Simdax & Comtan has partly compensated for the decline. 7% Easyhaler 7% ● Budesonide-formoterol Easyhaler product
Slide 9: Parkinson's drugs
Parkinson’s drugs Sales, EUR million Sales of Orion’s 60 branded Parkinson’s drugs 50 by market area MAT6/2017* 40 3% 30 20 Europe 28% 39% 10 Japan 0 ROW Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3 USA 2013 2014 2015 2016 2017 30% Orion sales Deliveries to Novartis *Source: IMS Health sales statistics MAT6
Slide 10: Easyhaler product family
Easyhaler product family ● Easyhaler product family sales grew by 18% Sales, EUR million − driven by budesonide-formoterol Easyhaler, 20 which grew by 44%. 18 16 ● Sales of budesonide-formoterol 14 have commenced in Germany and the United 12 Kingdom, as well as deliveries to Menarini in 10 Southern
Slide 11: Dexdor intensive care sedative
Dexdor intensive care sedative European sedative market Sales, EUR million MAT6/2017* 18 Total market value 16 EUR 536 million (+1%) 14 12 Propofol EUR 345 10 million (-1%) 12% 8 Midazolam EUR 66 6 11% million (-11%) 4 2 65% Dexmedetomidine 12% 0 EUR 59 million (+44%) Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q
Slide 12: Specialty Products
Specialty Products Net sales in key markets 1-9/2017 Breakdown of net sales vs. EUR million 1-9/2016 13% Finland Finland 217 0% Scandinavia 72 +19% Scandinavia 12% Eastern Europe and Eastern Europe Russia 47 +13% 56% & Russia 19% ROW ● Sales of biosimilar Remsima developed well, change in pricing sy
Slide 13: Orion strong in home market Finland
Orion strong in home market Finland Finnish human pharmaceuticals market 1-9/2017: Finland’s biggest ● Wholesale EUR 1,731 million pharmaceutical companies 1-9/2017, EUR million ● Orion's market share 13% 250 219 ● Growth of total market +2%, 200 Orion's growth 0% 150 – Changes to the pricing system
Slide 14: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Project Indication PHASE Registration Bioequivalence Easyhaler® salmeterol-fluticasone Asthma, COPD Registration study Darolutamide (ODM-201) 1) Prostate cancer (nmCRPC) I II III Darolutamide (ODM-201) 1) Prostate cancer (mHSPC) I II III ODM-109 (oral
Slide 15: Diagnostics business
Diagnostics business 15 26 October 2017 Interim Report 1-9/2017 © Orion Corporation
Slide 16: Orion Diagnostica
Orion Diagnostica 1-9/2016 1-9/2017 ● QuikRead® tests 41 39 remained the main product. 6.6 6.2 Net sales, Operating profit, EUR million EUR million -7% -6% 16 26 October 2017 Interim Report 1-9/2017 © Orion Corporation
Slide 17: Outlook for 2017
Outlook for 2017 (provided on 8 February 2017) Net sales are estimated to be Net sales at similar level to 2016 (net sales were EUR 1,074 million in 2016). Operating profit excluding material capital gains Operating profit is estimated to be at least EUR 280 million (operating profit excluding capit
Slide 18: Orion calendar 2018
Orion calendar 2018 Financial Statement Release for 2017 Wednesday 7 February 2018 Planned to be held on Annual General Meeting 2018 Tuesday 20 March 2018 Interim Report January–March 2018 Tuesday 24 April 2018 Half-Year Financial Report January–June 2018 Wednesday 18 July 2018 Interim Report Januar
Slide 19: Building well-being. Together.
Building well-being. Together.